Human Melanoma: Drug Resistance
- 1 January 2003
- book chapter
- Published by Springer Nature
- Vol. 161, 93-110
- https://doi.org/10.1007/978-3-642-19022-3_9
Abstract
Advanced malignant melanoma has a poor prognosis since chemotherapy is mostly ineffective because, in part, of the intrinsic and/or extrinsic resistance of melanoma cells to systemic treatment with antineoplastic agents. The reasons for the chemoresistant phenotype are currently unknown. The relevance of well-analyzed drug resistance mechanisms in melanoma such as intracellular and extracellular transport, drug resistance by induction of certain enzyme systems, and altered drug-target interaction is reviewed. It has been shown that most anticancer drugs kill susceptible cells through induction of apoptosis. Therefore, the significance of apoptotic deficiency caused by alteration in the apoptotic pathway is discussed in relation to specific molecules and apoptotic mechanisms like death-receptors, the Bcl-2 family, and the Hsp family of proteins. The complexity of the molecular variants involved in signal transduction along apoptotic pathways suggests that the cell may possess a variety of possibilities for regulating apoptosis and generating apoptosis deficiency. Thus apoptosis and apoptosis deficiency should be analyzed to understand the mechanisms of melanoma resistance.Keywords
This publication has 65 references indexed in Scilit:
- O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II studyInternational Journal of Cancer, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- Biochemical Pathways of Caspase Activation During ApoptosisAnnual Review of Cell and Developmental Biology, 1999
- Selective protection by hsp 70 against cytotoxic drug‐, but not Fas‐induced T‐cell apoptosisImmunology, 1999
- THE CENTRAL EFFECTORS OF CELL DEATH IN THE IMMUNE SYSTEMAnnual Review of Immunology, 1999
- The role of multidrug resistance-associated protein (MRP) expression in multidrug resistanceAnti-Cancer Drugs, 1997
- Bcl-2 expression in malignant melanoma and its prognostic significanceEuropean Journal of Surgical Oncology, 1996
- Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivityCancer, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cellsMelanoma Research, 1992